Form 4: Protagonist Therapeutics CEO Sells Shares Following PSU Vesting
Insider Transaction Report
Protagonist Therapeutics' President and CEO, Dinesh V. Patel, acquired 25,000 shares from vested performance stock units and subsequently sold a total of 52,444 shares, including those to cover tax obligations.
Summary
- Dinesh V. Patel, President and CEO of Protagonist Therapeutics, Inc. (PTGX), acquired 25,000 shares of common stock on July 21, 2025, through the settlement of performance stock units (PSUs).
- These PSUs were granted on February 26, 2021, under the company's 2016 Equity Incentive Plan and vested due to the achievement of corporate performance objectives.
- On July 21, 2025, Patel sold 12,859 shares at $54.86 to cover tax withholding obligations related to the PSU settlement.
- Further sales occurred on July 22, 2025, with 22,065 shares sold at a weighted average price of $55.05 (ranging from $55.00 to $55.19).
- On July 23, 2025, an additional 17,520 shares were sold at a weighted average price of $54.79 (ranging from $54.75 to $55.00).
- Following these transactions, Patel's direct beneficial ownership stands at 531,018 shares of common stock.
Sentiment
Score: 4
Explanation: The vesting of performance stock units is positive, indicating corporate performance objectives were met. However, the subsequent significant selling of shares by the CEO, beyond what was required for tax obligations, introduces a negative sentiment as it could be perceived as a lack of strong conviction in the company's near-term stock performance.
Positives
- Vesting of 25,000 performance stock units indicates the achievement of corporate performance objectives.
Negatives
- Significant insider selling of 52,444 shares over three days, beyond just tax-related sales.
Future Outlook
No forward-looking statements or guidance are provided in this filing.
Industry Context
This filing is a standard insider transaction report and does not provide broader industry context. It reflects an executive's compensation and personal trading activity.
Stakeholder Impact
- Shareholders: The sale of shares by a key executive could be interpreted negatively, potentially leading to a decrease in investor confidence or downward pressure on the stock price.
- Employees: The vesting of PSUs indicates the company met performance objectives, which could be positive for employee morale and future incentive plans.
Key Dates
| Date | Description |
|---|---|
| February 26, 2021 | Date performance stock units (PSUs) were granted to Dinesh V. Patel under the Issuer's 2016 Equity Incentive Plan. |
| July 21, 2025 | Date of acquisition of 25,000 shares from PSU settlement and sale of 12,859 shares to cover tax withholding. |
| July 22, 2025 | Date of sale of 22,065 shares of common stock. |
| July 23, 2025 | Date of sale of 17,520 shares of common stock and signature date of the filing. |
Recommendation
holdWhile the vesting of performance stock units is a positive indicator of the company meeting its corporate objectives, the subsequent significant selling of shares by the CEO, beyond tax obligations, introduces a degree of caution. This insider selling could signal a lack of strong conviction in the immediate upside or a desire for personal diversification. Given the mixed signals, a 'hold' recommendation is prudent, advising investors to monitor future insider activity and company performance before making further investment decisions.
Keywords
Protagonist Therapeutics, PTGX, Dinesh V. Patel, Insider Trading, SEC Form 4, Stock Sales, Performance Stock Units, PSU Vesting, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.